Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors while in the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations research found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://johnc159bee5.wikiannouncing.com/user